Amylyx Pharmaceuticals (AMLX)
(Delayed Data from NSDQ)
$2.16 USD
-0.06 (-2.70%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $2.16 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Amylyx Pharmaceuticals, Inc. [AMLX]
Reports for Purchase
Showing records 1 - 20 ( 32 total )
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Avexitide?s Potential Beyond PBH and CHI Remains Undervalued
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Phase 2 Validated Avexitide Open Opportunities in Metabolic Disorder Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Calpain is a Well Validated Target for ALS and other Neurodegenerative Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Interim HELIOS Data Encouraging, Supports C-Peptide as a Surrogate Endpoint in Wolfram
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Biomarker Data from HELIOS has the Potential to Restore Confidence in AMX0035
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
From the Ashes of Phoenix a New Focus Rises in Wolfram Syndrome and PSP; Reiterate Buy and PT Down to $8
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Investment in Developing ALS Biomarker Panel Important for Company?s Dominance in the ALS Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for AMLX 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Relyvrio Discontinuation Rate at Par or Better Than Competitors; Reiterate Buy and PT Down to $42
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Negative Opinion on AMX0035 Shows Challenges with CHMP?s Assessment of Neurology Disease Trials
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Acces Compassionnel Coupled with Real World Safety Data Encouraging Ahead of CHMP Decision
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Amylyx Has A Stronger Case Over Other Drugs Approved Under CMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Thoughts on the Next Steps Post CHMP?s Regulatory Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Thoughts on AMX0114, An Anti-Sense Oligo Targeting Calpain-2; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Importance of Real World Evidence in Drug Approvals-Insights From AD/PD 2023 Gothenburg
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Relyvrio Survival Data is Key for Encouraging Launch; Reit. Buy and PT $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
Broadening Payer Coverage by 1H23 Might Be the Growth Driver For Relyvrio
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amylyx Pharmaceuticals, Inc.
Industry: Medical - Drugs
A Snapshot of Novel Targets in Parkinson?s Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A